Visa enkel post

dc.contributor.authorHolmgren, Gustav
dc.date.accessioned2016-11-23T10:25:10Z
dc.date.available2016-11-23T10:25:10Z
dc.date.issued2016-11-23
dc.identifier.isbn978-91-629-0002-1 (PDF)
dc.identifier.isbn978-91-629-0001-4 (Print)
dc.identifier.urihttp://hdl.handle.net/2077/47401
dc.description.abstractToxicity testing of chemicals, drug candidates, and food additives is in need of a change. The present methods, mainly consisting of animal models with their associated ethical concerns, are expensive, time-consuming, and importantly they are often poor predictors of the human in vivo toxicity. With the rapid biotechnology development, a paradigm shift for toxicity testing is emerging, focusing on bioinformatics, computational toxicity, systems biology, and cell-based in vitro models. The aim of this thesis was to investigate the utility of using cells, i.e. hepatocytes and cardiomyocytes, derived from human pluripotent stem cells (hPSC) as in vitro models for toxicity testing. The first part explored the feasibility of using hPSC-derived hepatocytes to study toxic drug exposure, and in addition investigated the relevancy of the cellular response. The second and major part of this thesis focused on hPSC-derived cardiomyocytes and the in-depth study of doxorubicin-induced toxicity. The studies revealed that the differentiation processes and culturing of hPSC-derivatives are stable and reproducible to form the basis for in vitro models for toxicity testing, even for longer studies over two weeks. The hepatocytes and the cardiomyocytes showed sensitivity towards the toxic compounds and both cell models dis-played a relevant cellular response to the toxic exposure. For example, the hepatocytes showed evidence of steatosis and phospholipidosis when incubated with hepatotoxic compounds over time. Besides an evident effect of doxorubicin on the cardiomyocyte function, the cells also proved to be useful for more in-depth mechanistic evaluations, as these studies gave insight, on multiple biological levels, in plausible mechanisms and identified potential biomarkers for doxorubicin-induced cardiotoxicity. In conclusion, this thesis presents findings that supports the vision and strategy of using in vitro models based on hPSC-derivatives together with advanced omics technologies for toxicity testing and risk assessment of drugs, food additives, and chemicals.sv
dc.language.isoengsv
dc.relation.haspartI. Holmgren, G., Sjögren A. K., Barragan I., Sabirsh A.,. Sartipy P, Synnergren J., Bjorquist P., Ingelman-Sundberg M., Andersson T. B., and Edsbagge J. Long-term chronic toxicity testing using human pluripotent stem cell-derived hepatocytes Drug Metab Dispos 42(9):1401-1406.2014 ::doi::10.1124/dmd.114.059154sv
dc.relation.haspartII. Holmgren, G., Synnergren J., Bogestal Y., Améen C., Akesson K., Holmgren S., Lindahl A., and Sartipy P. Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells Toxicology 328: 102-111. 2015 ::doi::10.1016/j.tox.2014.12.018sv
dc.relation.haspartIII. Holmgren, G., Synnergren, J., Andersson, C.X., Lindahl, A., and Sartipy, P. MicroRNAs as potential biomarkers for doxorubicin-induced cardiotoxicity Toxicol In vitro 34, 26-34. 2016 ::doi::10.1016/j.tiv.2016.03.009sv
dc.relation.haspartIV. Holmgren, G., Sartipy, P., Andersson, C.X., Lindahl, A., and Synnergren, J. Expression profiling of human pluripotent stem cell-derived cardiomyocytes exposed to doxorubicin – integration and visualization of multi omics data Manuscriptsv
dc.subjecttoxicity testingsv
dc.subjecthuman pluripotent stem cellssv
dc.subjectcardiomyocytessv
dc.subjecthepatocytessv
dc.subjectmicroarraysv
dc.subjectquantitative proteomicssv
dc.subjectbioinformaticssv
dc.subjecttranscriptomicssv
dc.subjectmicroRNAsv
dc.titleIn vitro toxicity testing using human pluripotent stem cell derivativessv
dc.typetexteng
dc.type.svepDoctoral thesiseng
dc.type.degreeDoctor of Philosophy (Medicine)sv
dc.gup.originUniversity of Gothenburg. Sahlgrenska Academysv
dc.gup.departmentInstitute of Biomedicine. Department of Clinical Chemistry and Transfusion Medicinesv
dc.gup.defenceplaceTorsdagen den 15 december, klockan 9.00, Biotech-huset, Arvid Wallgrens Backe 20, Göteborgsv
dc.gup.defencedate2016-12-15
dc.gup.dissdb-fakultetSA


Filer under denna titel

Thumbnail
Thumbnail
Thumbnail

Dokumentet tillhör följande samling(ar)

Visa enkel post